Vigil Neuroscience Inc Says Phase 1 Dosing Expected To Commence In October 2023; No Anticipated Delays In Current Clinical Development Plans; IND For VG-3927 Now Open
Portfolio Pulse from Benzinga Newsdesk
Vigil Neuroscience Inc. has announced that Phase 1 dosing is expected to commence in October 2023, with no anticipated delays in current clinical development plans. The Investigational New Drug (IND) application for VG-3927 is now open.
September 08, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vigil Neuroscience's announcement of the commencement of Phase 1 dosing in October 2023 and the opening of the IND for VG-3927 could potentially boost investor confidence.
The announcement of the commencement of Phase 1 dosing and the opening of the IND for VG-3927 indicates progress in Vigil Neuroscience's clinical development plans. This could potentially boost investor confidence and have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100